Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

602
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
602
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

22
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

19
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

22
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Angina IV: Management01:26

Angina IV: Management

15
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
15
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease.

Journal of the American Heart Association·2026
Same author

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

JAMA cardiology·2026
Same author

Epigenetic Remodeling in Myocardial Reperfusion Injury: The Emerging Role of the ARID1A/SOX9 Axis.

Korean circulation journal·2026
Same author

From Risk Factors to Action: Preventing Stroke After Durable LVAD in the Contemporary Era.

Korean circulation journal·2026
Same author

2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes.

Korean circulation journal·2026
Same author

The Persistent Challenge of Cardiogenic Shock Complicating Acute Myocardial Infarction: Insights From a Korean Nationwide Registry.

Korean circulation journal·2026

関連する実験動画

Updated: Aug 22, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

アスピリン 対 クロピドグレル 経皮冠動脈手術後の長期維持単療法: HOST- EXAM 拡張研究

Jeehoon Kang1, Kyung Woo Park1, Huijin Lee1

  • 1Seoul National University Hospital, Korea (J.K., K.W.P., H.L., D.H., H.-M.Y., J.-K.H., B.-K.K., H.-S.K.).

Circulation
|November 7, 2022
PubMed
まとめ
この要約は機械生成です。

薬剤排出ステントによる冠動脈介入後のクロピドグレル単独治療は,アスピリンと比較して重大な有害事象を著しく減少させた. この延長された追跡調査は,クロピドグレルの有効性を確認した.

キーワード:
経皮冠動脈介入血小板凝集阻害剤治療の結果

さらに関連する動画

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

関連する実験動画

Last Updated: Aug 22, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床試験

背景:

  • 薬剤排出ステント (DES) を用いた経皮冠動脈干渉 (PCI) の後の抗血小板単体治療の長期的なアウトカムについては,まだ完全に理解されていません.
  • HOST- EXAM 拡張試験は,抗血小板単体療法に関する重要な追跡データを提供しています.

研究 の 目的:

  • クロピドグレル単独治療とアスピリン単独治療の長期的な有効性と安全性を評価する.
  • クロピドグレルとアスピリンの単独治療群の総合的な臨床結果,血栓性イベント,出血イベントを比較する.

主な方法:

  • DES- PCIを患った患者54, 38人が,対抗血小板治療を12ヶ月±6ヶ月間受け,クロピドグレルまたはアスピリン単独療法にランダムに割り当てられました.
  • 主要エンドポイント: 死亡,心筋梗塞,脳卒中,ACS再入院,BARC ≥3の出血.
  • 二次的エンドポイント: 長期追跡期間中に分析された血栓と出血.

主要な成果:

  • クロピドグレル単独治療では,初等複合エンドポイントの発生率は12. 8% vs 16. 9% ,HR 0. 74,P< 0. 001) が平均5. 8年にわたって有意に低下した.
  • クロピドグレルの二次性血栓症 (HR 0. 66, P< 0. 001) と出血のエンドポイント (HR 0. 74, P=0. 016) のリスクの低下が観察されました.
  • グループ間の全因死亡率の有意な差は認められなかった (P=0. 742); クロピドグレルの長期間での効果は一貫していた.

結論:

  • クロピドグレルの単独治療は,特定のPCI患者でアスピリンの単独治療と比較して優れた長期的な臨床結果と関連しています.
  • これらの結果は,PCI後の出血リスクを管理しながら,不血症イベントを減らすための潜在的により効果的な戦略として,クロピドグレル単独療法を支持しています.